lovastatin effect in preventing of contrast induced acute kidney injury
Not Applicable
- Conditions
- Contrast induced acute kidney injury.Other acute renal failure
- Registration Number
- IRCT2017041033359N1
- Lead Sponsor
- Vice Chancellor for research of kurdistan University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 122
Inclusion Criteria
patients that need intravenous contrast administration.
Exclusion criteria: Acute kidney injury; acute coronary syndrome and acute myocardial infarction; statin sensitivity; patients Dissatisfaction
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Acute kidney injury. Timepoint: Basline and 4h hours after diagnostic intervention. Method of measurement: Serum creatinine and MDRD e GFR.;Acute kidney injury. Timepoint: 48 h after intervention. Method of measurement: Serum creatinine and MDRD e GFR.
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie lovastatin's nephroprotective effects in contrast-induced acute kidney injury?
How does high-dose lovastatin compare to N-acetylcysteine in preventing CI-AKI based on IRCT2017041033359N1 outcomes?
Which biomarkers correlate with lovastatin response in patients at risk for contrast-induced nephropathy?
What are the adverse event profiles of short-term high-dose lovastatin versus standard-of-care in CI-AKI prevention?
How do statin-based therapies like rosuvastatin or atorvastatin compare to lovastatin in mitigating IV contrast-induced renal injury?